Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Northwest Bioth Cmn (NWBO)

Northwest Bioth Cmn (NWBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,129,580
  • Shares Outstanding, K 842,970
  • Annual Sales, $ 1,290 K
  • Annual Income, $ -529,820 K
  • 60-Month Beta 0.86
  • Price/Sales 842.32
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NWBO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +9.84%
on 04/16/21
1.7500 -23.43%
on 03/23/21
-0.1950 (-12.70%)
since 03/16/21
3-Month
1.0100 +32.67%
on 02/23/21
1.8000 -25.56%
on 03/15/21
-0.0100 (-0.74%)
since 01/15/21
52-Week
0.1521 +781.00%
on 04/21/20
2.5100 -46.61%
on 10/20/20
+1.1600 (+644.44%)
since 04/16/20

Most Recent Stories

More News
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breach of Fiduciary Duty Claims

NEW YORK, NY / ACCESSWIRE / April 17, 2021 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Northwest Biotherapeutics, Inc. ()....

NWBO : 1.3400 (+3.88%)
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that development...

NWBO : 1.3400 (+3.88%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

, /PRNewswire/ --   -  The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries...

ONCY : 2.99 (+2.05%)
ONC.TO : 3.72 (+0.54%)
INO : 8.74 (-3.00%)
REGN : 502.60 (+1.61%)
SNY : 51.30 (+1.20%)
NWBO : 1.3400 (+3.88%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent ...

ONCY : 2.99 (+2.05%)
INO : 8.74 (-3.00%)
REGN : 502.60 (+1.61%)
SNY : 51.30 (+1.20%)
NWBO : 1.3400 (+3.88%)
ONC.TO : 3.72 (+0.54%)
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market

, /PRNewswire/ -- Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with...

ATNM : 7.46 (-1.45%)
AZN : 50.74 (-0.18%)
BMY : 65.46 (+1.58%)
MRK : 77.47 (+1.06%)
NWBO : 1.3400 (+3.88%)
Northwest Biotherapeutics Announces Data Lock of Phase III Trial

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that the database...

NWBO : 1.3400 (+3.88%)
Northwest Biotherapeutics Acquires Flaskworks

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that the Company...

NWBO : 1.3400 (+3.88%)
NW Bio Accelerating Sawston Plant Phase I Buildout

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that the Company...

NWBO : 1.3400 (+3.88%)
Northwest Biotherapeutics Announces $5 Million Financing

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that the Company has...

NWBO : 1.3400 (+3.88%)
NW Bio Announces Completion of Further Data Gathering For Phase III Trial

, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining...

NWBO : 1.3400 (+3.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 1.5167
2nd Resistance Point 1.4333
1st Resistance Point 1.3867
Last Price 1.3400
1st Support Level 1.2567
2nd Support Level 1.1733
3rd Support Level 1.1267

See More

52-Week High 2.5100
Fibonacci 61.8% 1.6093
Last Price 1.3400
Fibonacci 50% 1.3311
Fibonacci 38.2% 1.0528
52-Week Low 0.1521

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar